Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study. / Dalgard, Olav; Weiland, Ola; Noraberg, Geir; Karlsen, Lars; Heggelund, Lars; Färkkilâ, Martti; Balslev, Ulla; Belard, Erika; Øvrehus, Anne; Skalshøi Kjær, Mette; Krarup, Henrik; Thorup Røge, Birgit; Hallager, Sofie; Madsen, Lone G; Lund Laursen, Alex; Lagging, Martin; Weis, Nina.
In: PloS one, Vol. 12, No. 7, e0179764, 13.07.2017.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study
AU - Dalgard, Olav
AU - Weiland, Ola
AU - Noraberg, Geir
AU - Karlsen, Lars
AU - Heggelund, Lars
AU - Färkkilâ, Martti
AU - Balslev, Ulla
AU - Belard, Erika
AU - Øvrehus, Anne
AU - Skalshøi Kjær, Mette
AU - Krarup, Henrik
AU - Thorup Røge, Birgit
AU - Hallager, Sofie
AU - Madsen, Lone G
AU - Lund Laursen, Alex
AU - Lagging, Martin
AU - Weis, Nina
PY - 2017/7/13
Y1 - 2017/7/13
N2 - BACKGROUND AND AIMS: Chronic hepatitis C virus (HCV) genotype 3 infection with advanced liver disease has emerged as the most challenging to treat. We retrospectively assessed the treatment outcome of sofosbuvir (SOF) based regimes for treatment of HCV genotype 3 infections in a real life setting in Scandinavia.METHODS: Consecutive patients with chronic HCV genotype 3 infection were enrolled at 16 treatment centers in Denmark, Sweden, Norway and Finland. Patients who had received a SOF containing regimen were included. The fibrosis stage was evaluated by liver biopsy or transient liver elastography. The following treatments were given according availability and local guidelines: 1) SOF + ribavirin (RBV) for 24 weeks, 2) SOF + daclatasvir (DCV) +/-RBV for 12-24 weeks, 3) SOF + pegylated interferon alpha (peg-IFN-α) + RBV for 12 weeks or 4) SOF/ledipasvir (LDV) + RBV for 12-16 weeks. The primary endpoint was sustained virological response (SVR) assessed at week 12 (SVR12) after end of treatment.RESULTS: We included 316 patients with a mean age of 55 years (range 24-79), 70% men, 49% treatment experienced, 58% with compensated cirrhosis and 12% with decompensated cirrhosis.In the modified intention to treat (mITT) population SVR12 was achieved in 284/311 (91%) patients. Among 26 treatment failures, five had non-response, 3 breakthrough and 18 relapse. Five patients were not included in the mITT population. Three patients died from reasons unrelated to treatment and two were lost to follow-up. The SVR12 rate was similar for all treatment regimens, but lower in men (p = 0.042), and in patients with decompensated liver disease (p = 0.004).CONCLUSION: We found that sofosbuvir based treatment in a real-life setting could offer SVR rates exceeding 90% in patients with HCV genotype 3 infection and advanced liver disease.
AB - BACKGROUND AND AIMS: Chronic hepatitis C virus (HCV) genotype 3 infection with advanced liver disease has emerged as the most challenging to treat. We retrospectively assessed the treatment outcome of sofosbuvir (SOF) based regimes for treatment of HCV genotype 3 infections in a real life setting in Scandinavia.METHODS: Consecutive patients with chronic HCV genotype 3 infection were enrolled at 16 treatment centers in Denmark, Sweden, Norway and Finland. Patients who had received a SOF containing regimen were included. The fibrosis stage was evaluated by liver biopsy or transient liver elastography. The following treatments were given according availability and local guidelines: 1) SOF + ribavirin (RBV) for 24 weeks, 2) SOF + daclatasvir (DCV) +/-RBV for 12-24 weeks, 3) SOF + pegylated interferon alpha (peg-IFN-α) + RBV for 12 weeks or 4) SOF/ledipasvir (LDV) + RBV for 12-16 weeks. The primary endpoint was sustained virological response (SVR) assessed at week 12 (SVR12) after end of treatment.RESULTS: We included 316 patients with a mean age of 55 years (range 24-79), 70% men, 49% treatment experienced, 58% with compensated cirrhosis and 12% with decompensated cirrhosis.In the modified intention to treat (mITT) population SVR12 was achieved in 284/311 (91%) patients. Among 26 treatment failures, five had non-response, 3 breakthrough and 18 relapse. Five patients were not included in the mITT population. Three patients died from reasons unrelated to treatment and two were lost to follow-up. The SVR12 rate was similar for all treatment regimens, but lower in men (p = 0.042), and in patients with decompensated liver disease (p = 0.004).CONCLUSION: We found that sofosbuvir based treatment in a real-life setting could offer SVR rates exceeding 90% in patients with HCV genotype 3 infection and advanced liver disease.
KW - Adult
KW - Aged
KW - Antiviral Agents
KW - Drug Therapy, Combination
KW - Female
KW - Genotype
KW - Hepacivirus
KW - Hepatitis C, Chronic
KW - Humans
KW - Imidazoles
KW - Interferon-alpha
KW - Male
KW - Middle Aged
KW - Retrospective Studies
KW - Ribavirin
KW - Scandinavian and Nordic Countries
KW - Sofosbuvir
KW - Sustained Virologic Response
KW - Treatment Outcome
KW - Journal Article
KW - Multicenter Study
U2 - 10.1371/journal.pone.0179764
DO - 10.1371/journal.pone.0179764
M3 - Journal article
C2 - 28704381
VL - 12
JO - PLoS ONE
JF - PLoS ONE
SN - 1932-6203
IS - 7
M1 - e0179764
ER -
ID: 183608413